TY - JOUR
T1 - Treatment resistant schizophrenia
T2 - Course of brain structure and function
AU - Harvey, Philip D.
AU - Rosenthal, Jennifer B.
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 2016
Y1 - 2016
N2 - Approximately 30% of people with schizophrenia manifest a minimal response to conventional and atypical antipsychotic medications and manifest continuous symptoms of psychosis, with this condition referred to as “treatment resistant schizophrenia (TRS)”. There are several neurobiological consequences of continuous psychosis, including regional cortical atrophy and ventricular enlargement. Pharmacological treatments are available for TRS, with at least 1/3 of patients responding to treatment with clozapine. In this paper we review the evidence regarding the course of treatment resistant schizophrenia, as well as changes in brain structure and function in psychosis and on the possible role of clozapine treatment in altering cortical deterioration in patients with TRS.
AB - Approximately 30% of people with schizophrenia manifest a minimal response to conventional and atypical antipsychotic medications and manifest continuous symptoms of psychosis, with this condition referred to as “treatment resistant schizophrenia (TRS)”. There are several neurobiological consequences of continuous psychosis, including regional cortical atrophy and ventricular enlargement. Pharmacological treatments are available for TRS, with at least 1/3 of patients responding to treatment with clozapine. In this paper we review the evidence regarding the course of treatment resistant schizophrenia, as well as changes in brain structure and function in psychosis and on the possible role of clozapine treatment in altering cortical deterioration in patients with TRS.
KW - Clozapine
KW - Schizophrenia
KW - Treatment resistance
UR - http://www.scopus.com/inward/record.url?scp=84959452761&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959452761&partnerID=8YFLogxK
U2 - 10.1016/j.pnpbp.2016.02.008
DO - 10.1016/j.pnpbp.2016.02.008
M3 - Review article
C2 - 26925705
AN - SCOPUS:84959452761
VL - 70
SP - 111
EP - 116
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry
SN - 0278-5846
ER -